Latest Anemia News
A high erythropoietin resistance index was associated with triple the risk for death from any cause.
Patients provided small doses of intravenous iron per treatment achieved higher hemoglobin levels than patients receiving weekly iron.
In a small study, 82% of patients had iron overload prior to hemodialysis initiation.
Less than half of anemic patients were prescribed ESAs or iron in the US and France, and a high percentage overall did not have iron indices measured.
Investigators find that the normalized mean ESA dose decreases as patients' elevation of residence increases.
Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin.
New findings implicate transferrin saturation and nutritional status assessed by albumin.
After 54 weeks of treatment with testosterone undecanoate, anemia prevalence decreased from 29.6% to 10%.
Trend is independent of intravenous iron use and exposure to erythropoiesis-stimulating agents.
No new adverse events observed in patients with underlying cardiovascular risk factors who switched to continuous erythropoietin receptor activator.
Greater hyporesponsiveness to erythropoiesis-stimulating agents was associated with increased PLR ratios.
Observed rates of all-cause and cardiovascular mortality and myocardial infarction were consistent with expected rates, study shows.
Researchers observe significantly higher levels of albumin and hemoglobin and better calcium and phosphate metabolism.
Based on effect of erythropoietin-stimulating agents for higher hemoglobin targets.
In a phase 2 trial, roxadustat maintained hemoglobin levels over 19 weeks as well as epoetin alfa.
- Blacks With Diabetes and CKD Have Higher CVD Risk
- Worse Re-transplant Outcomes for HIV Positive Patients
- Race, Procedure Type Influence Morbidity in Pediatric Surgery Patients
- Parathyroidectomy Rates Stable Despite Changes in Medical Therapy
- Early Recurrence After Laparoscopic Radical Cystectomy Explored